Top 10 Medical Stocks To Watch Right Now

As a value investor, one of my top rules comes from a quote by Warren Buffett warning investors not to buy into hype: “Be fearful when others are greedy and greedy when others are fearful.”

Following this advice, its time to dig deep to find value in today’s bull market. Even The Economist featured a cover this week with a menacing golden bull charging through a concrete wall with the words “Wall Street is back”. 

To find long-term value in surging markets sometimes its best to dive into the discount bin. In the video below, energy analysts Joel South and Taylor Muckerman look into the lagging energy sector to find a rare gem in Devon Energy (NYSE: DVN  ) . This exploration and production company is trading significantly under its net asset value as the market continues to punish energy producers who hold significant natural gas assets in addition to oil sands acreage. 

With natural gas spot prices moving higher, in addition to Devon’s 12%-20% oil growth this year, Devon presents a unique value proposition. In addition, the company has an incredible balance sheet which offers investors a safe haven while the company grows its liquids production over the long term.

Top 10 Medical Stocks To Watch Right Now: Insys Therapeutics Inc (INSY)

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company’s pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company’s product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with we ight loss in patients with acquired immune deficiency syndrome (AIDS).

Subsys

The Company’s Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.

Dronabinol Product Family

The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Caps ule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.

Cancer Therapeutics

In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.

The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes P harma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Advisors’ Opinion:

  • [By Louis Navellier]

    INSYS Therapeutics (INSY) is a biotech company that focuses on developing pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Their products include drugs that help patients deal with pain form the disease and help alleviate nausea and pain from chemotherapy. The company reported earnings this week and both profits and sales have exploded higher.

  • [By Matt Jarzemsky]

    Among companies that went public in the U.S. last year, FireEye has seen the second-biggest share rally since its IPO, trailing only pharmaceutical company Insys Therapeutics Inc.(INSY)

Top 10 Medical Stocks To Watch Right Now: Mast Therapeutics Inc (MSTX)

Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company’s product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.

ANX-188 (purified poloxamer 188)

ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company’s purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.

ANX-514 (docetaxel for injectable emulsion)

ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug c ommonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.

Exelbine (vinorelbine injectable emulsion)

Exelbine is an emulsion formulation of the chemother apy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.

In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.

The Company compete s with GlaxoSmithKline, Provenge and Pfizer.

Advisors’ Opinion:

  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many…) planned biotech IPOs that have recently been announced publicly:

  • [By Lauren Pollock]

    Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.

Top 10 Medical Stocks To Watch Right Now: Atrion Corp (ATRI)

Atrion Corporation (Atrion), and its subsidiaries, develop and manufacture products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. During the year ended December 31, 2011, the Company’s fluid delivery products accounted for 38% of the Company’s revenues. These products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications, including anesthesia and oncology.

The Company’s cardiovascular products accounted for 29% of its revenues during 2011. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2), a technology that delivers essential fluids and medications to the heart during open-heart surgery. The MPS2 integrates key functions relating to the delivery of solutions to the heart, such as varying the rate and ratio of oxygenated blood, crystalloid, potassium and other additives, and controlling temperature, pressure and other variables to allow simpler, more flexible management of this process, indicating improved patient outcomes. The MPS2 is the device used in open-heart surgery that allows for the mixing of drugs into the bloodstream without diluting the blood. The MPS2 employs advanced pump, temperature control and microprocessor technologies and includes a line of disposable products. It also develops and manufactures other cardiovascular products that include cardiac surgery vacuum relief valves; Retract-O-Tape silicone vessel loops for retracting and occluding vessels in minimally inva! sive surgical procedures; inflation devices for balloon catheter dilation, stent deployment and fluid dispensing, and Clean-Cut rotating aortic punch and PerfectCut Aortotomy System, both of which are used in heart bypass surgery to make a precision opening in the heart for attachment of the bypass vessels.

The Company’s ophthalmic products accounted for 17% of its revenues during 2011. The Company is a manufacturer of contact lens disinfection cases. It also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. The Company’s other medical and non-medical products accounted for 16% of its revenues during 2011. These product lines consist of instrumentation and associated disposables used to measure the activated clotting time of blood. In addition, it manufactures and sells a line of products designed for safe needle and scalpel blade containment. It is also the manufacturer of inflation syst ems and valves used in marine and aviation safety products. The Company manufactures inflation systems and valves for products, such as life vests, life rafts, inflatable boats, survival equipment and other inflatable structures. The Company also produces one-way and two-way pressure relief valves for use on electronics cases, munitions cases, pressure vessels, transportation container cases, escape slides, and many other medical and non-medical applications.

The Company market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It sells its products through a sales force which consists of direct sales personnel, independent sales representatives and distributors. It offers customer service, training and education, and technical support such as field service, spare parts, maintenance and repair for certain of its products. The Company’s medical products and other components are produced at facilities in ! Florida, ! Alabama and Texas.

Advisors’ Opinion:

  • [By Seth Jayson]

    There’s no foolproof way to know the future for ATRION (Nasdaq: ATRI  ) or any other company. However, certain clues may help you see potential stumbles before they happen — and before your stock craters as a result.

Top 10 Medical Stocks To Watch Right Now: IsoRay Inc (ISR)

IsoRay, Inc. (IsoRay), incorporated on June 15, 2004, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association (FDA) for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer. The seed may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. The Company has an existing distribution agreement with UralDial LLC (UralDial) that allows UralDial to distribute Proxcelan Cs-131 brachytherapy seeds in Russia. The Company, through UralDial, has regulatory approval to sell Cs-131 seeds in Russia. < /p>

IsoRay markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; lung cancer; ocular melanoma; head and neck cancers; colorectal cancer, brain cancer; and gynecological cancer. The Company focuses to market Cesium-131 for the treatment of other malignant disease, such as breast cancer, in the near future through the use of existing technologies that have received FDA-clearance. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). When placed into a nuclear reactor and exposed to a flux of neutrons, Ba-130 becomes Ba-131, the radioactive material that is the parent isotope of Cesium-131. The radioactive isotope Cesium-131 is normally produced by placing a quantity of stable non-radioactive barium (ideally barium enriched in isotope Ba-130) into the neutron flux of a nuclear reactor. The irradiation process converts a small fraction of this material into a radioactive form of ba rium (Ba-131). The Ba-131 decays by electron capture to the ! radioactive isotope of interest (Cesium-131).

As of June 30, 2011, IsoRay had agreements with several independent radiopharmacies to assay, preload, and sterilize loose seeds. During the fiscal year ended June 30, 2011, the Company loaded approximately 90% of Mick cartridges in the Company’s own facility, which accounted for approximately 61% of seeds sold. Approximately 33% of seeds sold are strand configurations, including strands preloaded in needles and the remaining 6% of seeds are sold as loose seeds.

Advisors’ Opinion:

  • [By James E. Brumley]

    I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that’s played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it’s earning the right to be compared to the likes of bigger brothers in the cancer-treatment space… names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).

Top 10 Medical Stocks To Watch Right Now: Koninklijke Philips NV (PHIA)

Koninklijke Philips NV, formerly Koninklijke Philips Electronics NV, is the Netherlands-based parent company of the Philips Group (Philips). The Company operates within three main business sectors, such as Healthcare, Consumer Lifestyle, and Lighting, as well as through the Innovation, Group & Services (IG&S) sector. The Healthcare sector offers both personal care and professional products, such as computer tomography equipment, radiography equipment and refurbished systems. Consumer Lifestyle sector offers a range of sound, vision, personal devices and household products, such as television, headphones, kitchen appliances, shavers and digital cameras, among others. Lighting sector offers lighting products, such as professional lamps, light-emitting diodes (LED), ballasts and luminaires, among others. The IG&S segment provides the operating sectors with support through shared service centers. It also includes projects which are not part of the operating sectors. Advisors’ Opinion:

  • [By Corinne Gretler]

    European stocks rose for a fourth day, extending a seven-week high, as companies from UBS AG to Royal Philips (PHIA) Electronics NV reported increased profit.

Top 10 Medical Stocks To Watch Right Now: Biodel Inc (BIOD)

Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).

The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI- based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.

Advisors’ Opinion:

  • [By Roberto Pedone]

    One under-$10 specialty biopharmaceutical player that’s starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.

    If you take a look at the chart for Biodel, you’ll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.

    Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.

    Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Medical Stocks To Watch Right Now: Therapeutic Solutions International Inc (TSOI)

Therapeutic Solutions International, Inc., formerly Friendly Auto Dealers, Inc., incorporated on August 6, 2007, is a development-stage company. The Company is focused in establishing itself as a specialized brand promotional merchandising company. It would identify a range of casual apparel and consumer products that can be manufactured and resold with the product endorsement of corporate logos. In April 2011, the Company acquired Splint Decisions Inc.

The Company concentrates its efforts in the People’s Republic of China and its retail automotive industry. As of December 31, 2009, the Company had no operations and had not generated any revenues.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap medical device or biotech related stocks Therapeutic Solutions International Inc (OTCMKTS: TSOI), diaDexus, Inc (OTCMKTS: DDXS) and Spherix Inc (NASDAQ: SPEX) have been getting some attention lately in various investment newsletters with the good news being that it appears none are the subject of paid promotions from stock promoters. So why are these three stocks all of a sudden getting some attention and what else do you need to know about them before you make a short or a long term bet on one? Here is a closer look at the whole picture and what you might be missing:

Top 10 Medical Stocks To Watch Right Now: Five Prime Therapeutics Inc (FPRX)

Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company’s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

FP-1039

FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.

FPA008

FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable diso rders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.

FPA144

FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor’s surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients’ t umors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.

Advisors’ Opinion:

  • [By John Kell and Tess Stynes var popups = dojo.query(“.socialByline .popC”); p]

    Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)

  • [By Monica Gerson]

    Breaking news

    Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.

    Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top 10 Medical Stocks To Watch Right Now: Conatus Pharmaceuticals Inc (CNAT)

Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company’s initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).

The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company’s 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Conatus Pharmaceuticals Inc.’s(CNAT) shares jumped 26% to $7.75 premarket after the biotechnology firm said its treatment for chronic liver disease has been granted a status that could mean quicker approval.

Top 10 Medical Stocks To Watch Right Now: Chromadex Corp (CDXC)

Chromadex Corporation, incorporated on June 19, 2008, is a provider of research and quality-control products and services to the natural products industry. The Company’s products are used by customers worldwide in the dietary supplement, food and beverage, cosmetic and pharmaceutical industries. The Company together with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and ingredients. On December 3, 2012, ChromaDex Inc. acquired Spherix Consulting Inc. The Company’s principal subsidiaries include ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc (Spherix).

The Company provides its clients in the food, supplement and pharmaceutical industries with solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations, and design and assessment of pre-clinical and clinical safety testing. It specializes in regulatory submissions for food and dietary supplement ingredients. For its clients involved in drug development within the pharmaceutical industry, the Company provides similar services, as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and investigational new drug writing.

Products and Services

The Company offers bulk raw materials for inclusion in dietary supplements, food, beverage and cosmetic products. Through its catalog, it supplies a range of products necessary to conduct quality control of raw materials and consumer products. The Company through Chromadex Analytics, provides a range of contract services ranging from routine contract analysis for the production of dietary sup! plements, cosmetics, foods and other natural products to elaborate contract research for clients in these industries. The Company provides a range of consulting services in the areas of regulatory support, new ingredient or product development, risk management and litigation support. With an addition of Spherix, it provides regulatory approval and scientific advisory services.

The Company competes with Sigma-Aldrich, Phytolab, US Pharmacopoeia, Extrasynthese, Covance, Eurofins, and Silliker Canada Co.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look: